Section 5 of 6
Economic information and modeling report
68 evidence topics · 28 sources
Modeling overview
Summary
No budget impact model, cost-effectiveness analysis, or health technology assessment of cretostimogene grenadenorepvec was found, and CG Oncology has announced no price. Its Form 10-K states that the “pricing of existing drugs may limit the amount we will be able to charge for our products”. Published U.S. economic evaluations in BCG-unresponsive high-risk NMIBC address the approved comparators. A Ferring-funded budget impact model of nadofaragene firadenovec estimated a budget impact of $0.0010 to $0.0084 per member per month over 3 years in a plan of one million members for CIS ± Ta/T1 disease, and $0.0064 to $0.0548 when papillary-only disease was included; the authors note that cretostimogene was “under investigation in ongoing trials for similar indications” and was not modeled. A 5-year Medicare Markov model found gemcitabine/docetaxel the most cost-effective option for a patient willing to try one line of therapy or proceed directly to radical cystectomy, radical cystectomy for a patient open to two lines of therapy or upfront radical cystectomy, and pembrolizumab for a patient willing to try up to 2 lines of FDA-approved therapy before radical cystectomy. A Johnson & Johnson-funded 15-month cost-per-responder model estimated that 43.5% of patients treated with TAR-200 achieved and sustained a complete response for at least 12 months, against 18.8% to 26.8% for pembrolizumab, nadofaragene firadenovec, and nogapendekin alfa inbakicept plus BCG without reinduction, and 10.1% for valrubicin. The 2020 ICER review estimated $151,000 per QALY gained for nadofaragene firadenovec and $114,000 for pembrolizumab against a hypothetical comparator with a 0% complete response rate, and a health-benefit price benchmark of $158,600 to $262,000 per year for nadofaragene firadenovec. Two other models found pembrolizumab not cost-effective at its price at the time, one estimating that a 5.4% price reduction would make it cost-effective, and a further analysis found nadofaragene firadenovec cost-effective against radical cystectomy at $10,014 per QALY at a willingness-to-pay threshold of $100,000. ImmunityBio reported preliminary results of a health economic analysis, based on complete response rates from an indirect treatment comparison, in which nogapendekin alfa inbakicept plus BCG had a lower cost per sustained complete responder than TAR-200.
Budget impact model, cost-effectiveness analysis, or health technology assessment of cretostimogene grenadenorepvec
No evidence found.
Cretostimogene grenadenorepvec in published economic models of the indication
Company statements on pricing of cretostimogene grenadenorepvec
Budget impact of nadofaragene firadenovec in a United States health plan
Cost-effectiveness of radical cystectomy and bladder-sparing treatments for BCG-unresponsive carcinoma in situ
“We developed a Markov decision analytic model to assess five treatments: RC, nadofaragene, nogapendekin, pembrolizumab, and gemcitabine/docetaxel.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For index patient 1, who is willing to try one line of therapy or proceed directly to RC, gemcitabine/docetaxel was the most cost-effective option. For index patient 2, open to two lines of therapy or upfront RC, RC was the most cost-effective. For index patient 3, willing to try up to 2 lines of FDA-approved therapy (pembrolizumab, nadofaragene, or nogapendekin) before RC, pembrolizumab was the most cost-effective option.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Current pricing of bladder-sparing treatments poses significant financial barriers, highlighting the need for better treatment selection tools and more equitable pricing.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cost per responder of TAR-200 versus FDA-approved comparators
ICER review of nadofaragene firadenovec, oportuzumab monatox, and pembrolizumab
“The Institute for Clinical and Economic Review (ICER) conducted a systematic literature review and cost-effectiveness analysis to evaluate the health and economic outcomes of nadofaragene firadenovec, oportuzumab monatox, and pembrolizumab for BCG-unresponsive NMIBC.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The base-case cost-effectiveness, with each drug compared with the hypothetical comparator with a 0% CR at 3 months, were $151,000 per QALY gained for nadofaragene firadenovec, $382,000 per QALY gained for oportuzumab monatox, and $114,000 per QALY gained for pembrolizumab.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The HBPB for nadofaragene firadenovec ranged from $158,600 to $262,000 per year.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cost-effectiveness of nadofaragene firadenovec and pembrolizumab versus a hypothetical alternative
“Nadofaragene firadenovec, at a placeholder price 10% higher than the price of pembrolizumab, had an incremental cost-effectiveness ratio of $263 000 and $145 000 per QALY gained in CIS and non-CIS populations, respectively. Pembrolizumab had an incremental cost-effectiveness ratio of $168 000 per QALY gained for CIS.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The cost-effectiveness of nadofaragene firadenovec will depend upon its price.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Cost-effectiveness of pembrolizumab versus salvage intravesical chemotherapy and radical cystectomy
Cost-effectiveness of approved bladder-sparing agents in a systematic review and Markov model
“Compared with using radical cystectomy to treat patients failing BCG therapy, at a willingness-to-pay threshold of 100 000 USD, nadofaragene firadenovec was cost effective, with an incremental cost-effectiveness ratio (ICER) of 10 014 USD per quality-adjusted life year (QALY), while nogapendekin alfa inbakicept was less cost effective than nadofaragene firadenovec (ICER of 44 602 USD per QALY). Pembrolizumab, which dominated, was both less costly and more effective than the other strategies.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Cost-effectiveness of salvage treatments in a German payer setting
“Considering a WTP of <€50 000/QALY, gemcitabine/docetaxel and HIVEC are highly cost-effective therapeutic options in BCG-refractory NMIBC, while RC remains the cheapest option. At its current price, pembrolizumab would only be cost-effective assuming a price reduction of at least 70%.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Manufacturer-reported cost-consequence analysis of nogapendekin alfa inbakicept plus BCG versus TAR-200
Budget impact model
Approach and framework
Budget impact model of cretostimogene grenadenorepvec: approach and framework
No evidence found.
Good-practice framework for budget impact analysis
“The key elements of a BIA include estimating the size of the eligible population, the current mix of treatments and the expected mix after the introduction of the new intervention, the cost of the treatment mixes, and any changes expected in condition-related costs.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Where possible, the BIA calculations should be performed by using a simple cost calculator approach because of its ease of use for budget holders.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Finally, the Task Force recommends that the analyst use the simplest design that will generate credible and transparent estimates.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The model should be consistent with that used for the CEA with regard to clinical and economic assumptions.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Structure of a published budget impact model of nadofaragene firadenovec
Potential budget impact method of the ICER review
Model structures of published cost-effectiveness and cost-per-responder analyses
“A Markov decision analytic model was created using TreeAge Pro software (TreeAge Software, Inc, Williamstown, Massachusetts).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Each treatment option modelled as a Markov node with health states including surveillance, treatment toxicity, recurrence, progression to MIBC, metastasis, and death (Figure 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We developed a de novo semi-Markov decision analytic model with model structure and inputs informed by key clinical trials, previous economic models, systematic literature reviews, and input from stakeholders (patients, advocacy groups, clinicians, payers, researchers, and manufacturers).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Perspective and time frame
Budget impact model of cretostimogene grenadenorepvec: perspective and time frame
No evidence found.
Perspective recommended for budget impact analysis
Perspective and time horizon of a published budget impact model of nadofaragene firadenovec
Perspective and time horizon of the ICER review
Perspectives and time horizons of other published analyses
“Cost-effectiveness was evaluated over a 5-year period using a willingness-to-pay threshold of $100,000 per quality-adjusted life-year from the US Medicare perspective.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Cycle length was set at 3 months with the model terminating after 20 cycles, representing a 5-year time horizon.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Epidemiology and eligible population inputs
Budget impact model of cretostimogene grenadenorepvec: eligible population inputs
No evidence found.
Company estimate of the addressable BCG-unresponsive population
Planned inclusion of papillary-only disease in the marketing application
Bladder cancer incidence and prevalence in the United States
Eligible population inputs in a published budget impact model
Eligible patients per one million health plan members
Projected market shares in a published budget impact model
Eligible prevalent population and uptake in the ICER review
Proportion of patients unresponsive to BCG
Proportion of patients who decline or are ineligible for radical cystectomy
Cost assumptions
Budget impact model of cretostimogene grenadenorepvec: cost assumptions
No evidence found.
Cretostimogene grenadenorepvec price
No evidence found.
Cretostimogene grenadenorepvec dosing schedule in BOND-003
Nadofaragene firadenovec wholesale acquisition cost
| Field | Value |
|---|---|
| NDC | “55566-1050-01” |
| Dosage form | “box” |
| Pack size | “4 vials x 20 ml” |
| WAC | “$62,740.70” |
Nadofaragene firadenovec dosing
Nogapendekin alfa inbakicept wholesale acquisition cost
| Field | Value |
|---|---|
| Marketed product | “ANKTIVA 400 mcg/0.4 mL” |
| NDC | “81481-803-01” |
| WAC price (400 mcg/0.4 mL vial) | “$35,800.00” |
Nogapendekin alfa inbakicept dosing
Pembrolizumab list price
Pembrolizumab dosing in BCG-unresponsive NMIBC
Gemcitabine intravesical system wholesale acquisition cost
No evidence found.
Gemcitabine intravesical system dosing
Medicare Part B payment limits for comparator agents, fourth quarter of 2026
| HCPCS code and product | Short description | HCPCS code dosage | Payment limit (USD) | Coinsurance percentage |
|---|---|---|---|---|
| J9029 nadofaragene firadenovec (Adstiladrin) | “Instill adstiladrin, tx dose” | “PER THERAPEUTIC DOSE” | “65200.563” | “20.000” |
| J9028 nogapendekin alfa inbakicept (Anktiva) | “Inj, nogapendekin pmln, 1mcg” | “1 MCG” | “94.139” | “20.000” |
| J9183 gemcitabine intravesical system (Inlexzo) | “Gemcitabine intravesical sys” | “225 MG” | “73054.053” | “20.000” |
| J9271 pembrolizumab (Keytruda) | “Inj pembrolizumab” | “1 MG” | “62.253” | “20.000” |
| J9030 BCG live intravesical | “Bcg live intravesical 1mg” | “1 MG” | “3.532” | “20.000” |
| J9357 valrubicin | “Valrubicin injection” | “200 MG” | “1230.664” | “20.000” |
| J9201 gemcitabine | “In gemcitabine hcl nos 200mg” | “200 MG” | “2.734” | “20.000” |
| J9171 docetaxel | “Docetaxel injection” | “1 MG” | “0.471” | “20.000” |
| J9280 mitomycin | “Mitomycin injection” | “5 MG” | “34.838” | “20.000” |
Medicare physician fee schedule relative value units for office-based instillation, surveillance, and evaluation services, 2026
| CPT code | Description | Non-facility total RVU | Facility total RVU | Conversion factor |
|---|---|---|---|---|
| 51720 | “Treatment of bladder lesion” | “2.75” | “1.14” | “33.4009” |
| 51701 | “Insert bladder catheter” | “1.36” | “0.66” | “33.4009” |
| 52000 | “Cystourethroscopy” | “6.46” | “2.13” | “33.4009” |
| 52204 | “Cystoscopy w/biopsy(s)” | “10.64” | “3.80” | “33.4009” |
| 88112 | “Cytopath cell enhance tech” | “1.96” | “1.96” | “33.4009” |
| 88120 | “Cytp urne 3-5 probes ea spec” | “16.23” | “16.23” | “33.4009” |
| 74178 | “Ct abd&plv wo cntr flwd cntr” | “10.12” | “10.12” | “33.4009” |
| 99214 | “Office o/p est mod 30 min” | “4.06” | “2.53” | “33.4009” |
Medicare physician fee schedule relative value units for transurethral resection and radical cystectomy, 2026
| CPT code | Description | Facility total RVU | Global days | Conversion factor |
|---|---|---|---|---|
| 52234 | “Cystoscopy and treatment” | “6.49” | “000” | “33.4009” |
| 52235 | “Cystoscopy and treatment” | “7.62” | “000” | “33.4009” |
| 52240 | “Cystoscopy and treatment” | “10.31” | “000” | “33.4009” |
| 51570 | “Removal of bladder” | “39.05” | “090” | “33.4009” |
| 51575 | “Removal of bladder & nodes” | “48.18” | “090” | “33.4009” |
| 51590 | “Remove bladder/revise tract” | “51.25” | “090” | “33.4009” |
| 51595 | “Remove bladder/revise tract” | “57.93” | “090” | “33.4009” |
| 51596 | “Remove bladder/create pouch” | “62.52” | “090” | “33.4009” |
Unit cost inputs in a published budget impact model
Three-month Medicare costs in a published cost-effectiveness model, 2024
“We calculated 2024 U.S. healthcare costs from a Medicare payer perspective. Costs were obtained for drugs, procedures, tests, and hospital admissions through Medicare payment schedules for CPT, DRG, and HCPCS codes (Table 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Treatment cost sources in a published cost-per-responder model
Placeholder drug prices in the ICER review
“Since the prices for nadofaragene firadenovec and oportuzumab monatox were not available at the time of the report, the price for nadofaragene firadenovec was set to equal the annual price of pembrolizumab ($164,337), whereas oportuzumab was set at $150,000 per year net of all rebates based on analyst estimates.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Costs of care after BCG with and without progression
“Total mean annualized costs per patient after BCG among those who progressed [$65,668 (SD $53,943)] were more than double compared with patients who did not [$29,780 ($36,425)].” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Annualized HRU and mean medical costs (2020 United States dollars) were estimated and compared between patients with versus without progression.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Costs of radical cystectomy in United States claims data
Model outcomes
Budget impact model of cretostimogene grenadenorepvec: model outcomes
No evidence found.
Outcomes recommended for budget impact analysis
“The outcomes of the BIA should be presented in the format of interest to health care decision makers.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In a computer program, options should be provided for different categories of costs to be included or excluded from the analysis.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“If a health condition model is needed for the BIA, it should reflect health outcomes and their related costs in the total affected population for each year after the new intervention is introduced into clinical practice.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Outcomes reported by published economic analyses in the indication
“The primary outcome was 5-year cost-effectiveness, measured by incremental cost-effectiveness ratio (ICER, calculated as incremental cost divided by incremental effectiveness) and net monetary benefit (NMB, calculated as willingness to pay [WTP] X effectiveness - cost).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For each population, we estimated time in progression-free state, total costs, total quality-adjusted life-years (QALYs), total equal value life-years gained (evLYGs), and total life-years (LYs) for each treatment over a lifetime time horizon.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Health-state utility values used in a published cost-effectiveness model
Results
Base case
Budget impact model of cretostimogene grenadenorepvec: base-case results
No evidence found.
Base-case budget impact of nadofaragene firadenovec in a plan of one million members
Potential budget impact of nadofaragene firadenovec in the ICER review
Base-case cost-effectiveness of radical cystectomy and bladder-sparing treatments over 5 years
Base-case cost per responder of TAR-200 versus FDA-approved comparators
Base-case incremental cost-effectiveness ratios in the ICER review, CIS ± Ta/T1
| Intervention | Cost per QALY gained | Cost per evLYG | Cost per year in progression-free state |
|---|---|---|---|
| Nadofaragene firadenovec | “$151,000”View highlighted excerpt for this quote | “$135,000”View highlighted excerpt for this quote | “$100,000”View highlighted excerpt for this quote |
| Oportuzumab monatox | “$382,000”View highlighted excerpt for this quote | “$343,000”View highlighted excerpt for this quote | “$281,000”View highlighted excerpt for this quote |
| Pembrolizumab | “$114,000”View highlighted excerpt for this quote | “$103,000”View highlighted excerpt for this quote | “$76,000”View highlighted excerpt for this quote |
Manufacturer-reported cost-consequence results for nogapendekin alfa inbakicept plus BCG versus TAR-200
Scenario analyses
Budget impact model of cretostimogene grenadenorepvec: scenario analyses
No evidence found.
Scenario and sensitivity analyses recommended for budget impact analysis
Scenario and sensitivity analyses of a published budget impact model
Sensitivity analyses of a published cost-effectiveness model
“Gemcitabine/docetaxel lost cost effectiveness compared to RC if the one-year recurrence free survival decreased from 60% to 50.4%, if the one-year progression free survival decreased from 97% to 92.2%, if the upstaging rate with delayed RC was greater than or equal to 36%, or if the three-month gemcitabine/docetaxel costs exceeded $8,808.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“One-way sensitivity analysis showed the model was sensitive to cost alone. Nadofaragene became cost effective with a 21% reduction in 3-month cost, while NAI-BCG would require a 67% cost reduction.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In a probabilistic sensitivity analysis with all model parameters varied simultaneously, the most cost-effective strategy remained pembrolizumab (54%), followed by nadofaragene (35%), and NAI-BCG (11%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Scenario and sensitivity analyses of a published cost-per-responder model
Scenario analyses in the ICER review
“In scenario analyses, when the CR of the hypothetical comparator was increased to 20% in the CIS ± Ta/T1 population, the incremental cost-effectiveness ratio for nadofaragene firadenovec and oportuzumab monatox increased to $155,000 and $407,000, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The model’s base-case assumption of an ineffective (0% CR) hypothetical comparator is likely overly conservative, so the base-case results can be viewed as the most optimistic scenario and should therefore be interpreted with caution.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Price reductions required for cost-effectiveness of pembrolizumab
Budget impact model discussion
Summary
Task force good-practice guidance lists the key elements of a budget impact analysis as the size of the eligible population, the current and expected treatment mix, the cost of each mix, and changes in condition-related costs, and recommends the perspective of the specific decision maker and presentation as a series of scenario analyses. For cretostimogene grenadenorepvec, two of these inputs are not yet available: a price, and a labeled population and dosing schedule. CG Oncology expects to complete its BLA “before the end of March 2027” and, after FDA feedback, plans to include high-grade papillary-only disease alongside CIS with or without papillary tumors.
The eligible population depends on which BCG-unresponsive disease is included. CG Oncology estimates up to 25,000 addressable patients with BCG-unresponsive NMIBC from internal research. In the nadofaragene firadenovec budget impact model of one million members, 5.5 adults with CIS ± Ta/T1 disease were eligible in Year 1, against 33.2 when papillary-only disease was added; that model applied 56.5% BCG treatment and 30% BCG unresponsiveness. The 2020 ICER review assumed 38% BCG non-response and derived 70,135 prevalent eligible individuals, of whom 18,956 (27%) had CIS. The authors of that model state that up to 80% of patients decline or are ineligible for cystectomy.
On costs, the Form 10-K describes cretostimogene as a six-week induction course, with three weekly maintenance doses every three months for the first 12 months and every six months for the next 24 months. Comparator list prices are $62,740.70 per Adstiladrin box (“4 vials x 20 ml”; instilled once every three months; October 2026), $35,800.00 per 400 mcg Anktiva vial (January 2025), and $25,034.88 per pembrolizumab dose given every 6 weeks (September 2026); no wholesale acquisition cost was found for the gemcitabine intravesical system, whose fourth-quarter 2026 Medicare Part B payment limit is $73,054.053 per 225 mg system. Each intravesical instillation also carries administration and surveillance costs (CPT 51720, 52000, 88112), and in the nadofaragene firadenovec model increased drug and administration costs were partially offset by savings from reduced progression, fewer cystectomies, and lower adverse event rates. In the published models, results were most influenced by uptake rate, drug cost, and target population size in the budget impact model, and the 5-year Markov model was sensitive to cost alone in one-way sensitivity analysis. The budget impact model and the cost-per-responder model were funded by Ferring Pharmaceuticals and Johnson & Johnson, and the nogapendekin alfa inbakicept analysis is a preliminary report from ImmunityBio.
Company statements on coverage and reimbursement of cretostimogene grenadenorepvec
Expected completion of the marketing application
Limitations stated by the authors of a published budget impact model
Pricing and coverage recommendations of the ICER review
“Manufacturers should set prices based on the added clinical value of treatments over lower-cost regimens. Leapfrogging these lower-cost regimens and setting prices relative to higher-cost options adds to the growing financial toxicity of oncology care.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“It seems likely that the FDA label for the emerging treatments will be limited to BCG-unresponsive patients, and payers may therefore wish to consider requiring documentation of a trial of BCG as a criterion for coverage.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Data sources recommended for budget impact inputs
“Data sources for the BIA should include published clinical trial estimates and comparator studies for the efficacy and safety of the current and new interventions as well as the decision maker's own population for the other parameter estimates, where possible.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote